• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19

byAndrew LeeandKiera Liblik
June 22, 2022
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to placebo, intramuscular AZD7442 had a relative risk reduction of 76.7% for symptomatic incident coronavirus disease 2019 (COVID-19).

2. At least one adverse event occurred in 35.3% of the AZD7442 group and 34.2% of the placebo group, these events were often mild or moderate in severity.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The COVID-19 pandemic has had a devastating impact on global health, with the approval of mRNA vaccines playing a critical role in prevention. Monoclonal antibodies are an important alternative for patients who are contraindicated from receiving currently available COVID-19 vaccines. Accordingly, AZD7442 is a combination of two human SARS-CoV-2-neutralizing monoclonal antibodies derived from patients infected with COVID-19 which can be injected intramuscularly. This randomized control trial compared the safety and efficacy of a single intramuscular dose of AZD7442 to a placebo control as pre-exposure prophylaxis to COVID-19. Symptomatic RT-PCR-positive illness occurred significantly less in the treatment group compared to the placebo group. The rate of adverse events was higher in the treatment group but was statistically insignificant. The most common adverse event was an injection-site reaction. This trial was limited by the low number of events in the smaller subgroups there compromising the ability to extrapolate results to important subgroups. The unblinding of some participants due to participants wanting to receive the COVID-19 vaccine.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

In-Depth [randomized control trial]: This randomized control trial compared the safety and efficacy of one intramuscular 300 mg dose of AZD7442 (n=3,460) to a placebo control (n=1,737) for preventing COVID-19 infection. The primary outcome was symptomatic and RT-PCR-positive COVID-19 within six-month follow-up. Symptomatic COVID-19 occurred in eight (0.2%) participants in the AZD7442 group and 17 participants (1.0%) in the placebo group (Relative Risk Reduction [RRR], 76.7%; 95% Confidence interval [CI], 46.0 to 90.9, p<0.001). At the median six-month follow-up, there was a lower incidence of COVID-19 in the AZD7442 group as compared to controls, with a relative risk reduction of 82.8% (95% CI, 65.8 to 91.4). The risk reduction was seen across all subgroups analyzed by age, sex, race/ethnicity, BMI, increased risk of COVID-19 exposure, and risk factors for severe covid-19. Additionally, 1,221 participants (35.3%) in the AZD7442 experienced at least one adverse event, compared to 593 participants (34.2%) in the placebo group. The most common adverse event was injection site reaction. All of the cases of severe or critical COVID-19 (n=5) and COVID-19-related deaths (n=2) occurred in the placebo group. Serum levels of AZD7442 remained at elevated levels 6 months after administration. Finally, viral genotypes for seven of 11 symptomatic participants in the treatment group and 13 out of 31 symptomatic participants in the placebo group. In total,11 of these symptomatic participants had variants of concern. In summary, AZD7442 may be effective as pre-exposure prophylaxis for COVID-19 in patients who are immunocompromised, contraindicated to receive the vaccinations, or cannot mount a sufficient response to the vaccination.

RELATED REPORTS

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States

Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: AZD7442COVID-19COVID-19 preventionCOVID-19 Vaccineinfectious diseasemonoclonal antibodiespublic healthvariants of concern
Previous Post

Magnetic resonance imaging-guided fibrosis ablation plus pulmonary vein isolation non-superior to pulmonary vein isolation alone in preventing atrial arrhythmia recurrence: The DECAAF II trial

Next Post

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

RelatedReports

RSV positivity associated with reduced serious bacterial infection risk [Classics Series]
Infectious Disease

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

June 24, 2022
Cardiovascular events in Kawasaki Disease not significantly elevated over controls
Chronic Disease

Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States

June 24, 2022
Masks for personal protection for SARS-CoV-2 infection
Infectious Disease

Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 23, 2022
Reduced doses of human papillomavirus vaccine may be effective in preventing condyloma
Public Health

Human papillomavirus vaccine effective in preventing infections in the United States

June 23, 2022
Next Post
Atrial fibrillation-specific management increases days alive and out of hospital

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

Reduced doses of human papillomavirus vaccine may be effective in preventing condyloma

Human papillomavirus vaccine effective in preventing infections in the United States

Provision of medically-tailored meals linked with lower admissions and medical spending

Wellness Check: Nutrition

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.